Health Costs

Prior to the first fall presidential debate, a growing share of voters see the election as a referendum on abortion access, and Vice President Harris holds a strong advantage over former President Trump on the issue. The economy and inflation remain voters’ top issue, and many want to hear the candidates address health care costs.

This brief describes the facts about actions taken under both the Trump and Biden Administrations related to capping insulin copayments for people with Medicare and explains the differences between their approaches.

This interactive tool, updated with 2022 data, helps users understand health care costs vary by family size, income, insurance, and health status. Use the dropdown menus to explore scenarios and trends in household health spending.

More than two years ago President Biden signed into law Medicare drug pricing provisions in the Inflation Reduction Act. KFF’s September Health Tracking Poll examines voter’s views on these provisions and finds that large majorities of voters are unaware of the provisions despite reporting support for them.

Allowing Medicare to negotiate drug prices on behalf of older Americans remains broadly popular across partisans, though many voters are unaware of the new law and the billions of dollars it is expected to save in 2026, a new KFF Health Tracking Poll finds.A large majority (85%) of voters say…

This issue brief draws from the KFF/LA Times Survey of Immigrants and other KFF analyses to highlight immigrants’ health care eligibility, healthcare use and costs, as well as their contributions to the economy and workforce.

This analysis examines the competitiveness of markets for hospital care based on the share of metropolitan areas controlled by a small number of independent hospitals or health systems and other measures. It finds that nearly half of metropolitan areas across the country had only one or two hospitals or health systems providing general inpatient hospital care in 2022.

This policy watch analyzes the latest data on Medicare Part D spending on GLP-1 drugs, initially approved to treat diabetes but in high demand as treatments for obesity, and shows how spending on these drugs has increased substantially in recent years.

A KFF analysis shows that gross total Medicare spending on Ozempic and other similar drugs has increased dramatically in recent years – even though Medicare is explicitly prohibited by law from covering the drugs for obesity. That’s because Medicare now covers the drugs, known as GLP-1s, for other medically accepted…

Mergers and acquisitions involving hospitals and other health care providers are drawing attention from federal and state regulators, including the Federal Trade Commission, and policymakers amid concerns that such consolidations can reduce competition and contribute to the high costs of health care. A new KFF brief examines and summarizes the…